Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Focused Clinical Review

The legacy context of general health and science information often serves as a foundational layer for public understanding of medical conditions and treatments. Within this broad domain, the dissemination of knowledge about prescription medications and their potential side effects has been a consistent theme. This heritage includes discussions of bisphosphonate therapies, such as Fosamax, which are commonly prescribed for bone density issues. As the public becomes more informed about medication risks, a natural progression occurs from general health awareness to more specific clinical concerns. One such concern involves the potential association between Fosamax exposure and the development of osteonecrosis of the jaw. This transition from a general health context to a focused clinical review requires careful consideration of the evidence base. The pivot from broad health information to a targeted examination of Fosamax and osteonecrosis of the jaw causation reflects a shift in focus from population-level health education to individual risk assessment. This movement underscores the importance of understanding how medication exposure, particularly in the context of long-term bisphosphonate use, may relate to specific adverse outcomes. The clinical evidence review thus becomes a critical tool for evaluating this potential link, moving beyond general health narratives to address specific patient safety questions.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The diagnosis is primarily clinical, based on the presence of exposed bone in the jaw that persists for more than eight weeks in the absence of prior radiation therapy. Imaging studies, such as panoramic radiographs or CT scans, may reveal bone sclerosis, sequestra, or periosteal reaction. A multiscale characterization of jawbone tissue has been developed to better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique microarchitecture and remodeling dynamics of the jawbone, which may predispose it to ONJ under bisphosphonate therapy.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. Its pharmacology involves binding to hydroxyapatite in bone and being internalized by osteoclasts during bone remodeling, leading to osteoclast apoptosis. While this mechanism is beneficial for osteoporosis, it can also suppress normal bone turnover, particularly in the jaw, where remodeling rates are high. The time to onset of ONJ symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in the general population but may be underreported in clinical trials due to short follow-up periods (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The pathogenesis of bisphosphonate-related ONJ is multifactorial. Fosamax's potent inhibition of osteoclast activity reduces bone remodeling, which can impair the repair of microdamage and the healing of dental extraction sites. This is compounded by the drug's anti-angiogenic properties, which may compromise blood supply to the jawbone. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The jawbone's unique characteristics, as elucidated by multiscale characterization, may further explain its susceptibility to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Anchors: Adequacy of Warnings and Causation Considerations

The prescribing information for Fosamax includes a warning under section 5.4 regarding osteonecrosis of the jaw, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For Fosamax Plus D, the warning further elaborates on risk factors and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings has been questioned, as the onset of symptoms can occur within days to months, and the condition may be misdiagnosed as common dental issues. For affected patients, causation considerations include the temporal relationship between Fosamax use and ONJ onset, the presence of other risk factors, and the exclusion of alternative causes such as radiation therapy or metastatic disease. The timeline between exposure and documented harm is variable, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a direct causal link in individual cases, but the recurrence of symptoms upon rechallenge provides strong evidence of a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Conclusion

The clinical evidence supports a causal association between Fosamax use and osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures or comorbidities. The mechanistic pathways involve suppressed bone remodeling and impaired healing, while the risk increases with longer exposure. Warnings in the prescribing information acknowledge this risk, but the variable onset and potential for misdiagnosis highlight the need for heightened clinical vigilance. Patients and healthcare providers should weigh the benefits of Fosamax in fracture prevention against the rare but serious risk of ONJ, especially when considering long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often associated with pain, swelling, and infection. It is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, reducing bone remodeling and impairing repair of microdamage and healing of dental extraction sites. Its anti-angiogenic properties may also compromise blood supply to the jawbone. Risk factors include invasive dental procedures, cancer, concomitant therapies, poor oral hygiene, and comorbidities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms of Fosamax-related ONJ?

Symptoms include exposed bone in the jaw, pain, swelling, and infection. Onset can vary from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Is there a warning about ONJ in Fosamax prescribing information?

Yes, the prescribing information includes a warning under section 5.4 about osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.